EDISON EQUITY RESEARCH: ALEXZA PHARMACEUTICALS - STILL AWAITING AN INFLECTION POINT IN ADASUVE GROWTH

Recent Adasuve orders from Alexza’s commercial partners, Teva and Ferrer, were below company expectations and reflect continued challenges to increasing sales momentum. Alexza intends to suspend Adasuve manufacturing in Q315 and may outsource production afterwards. The company will also need to raise funds by Q415 to fund operations, including its clinical studies for AZ-002 and AZ-007.

US-based Alexza Pharmaceuticals develops products for the acute treatment of CNS disorders using its proprietary Staccato rapid inhalation drug delivery system. Lead product Adasuve is approved in the US and EU for acute treatment of agitation in patients with schizophrenia or bipolar I disorder. 


To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports